PrognomiQ’s early lung cancer test achieves favorable outcomes
PrognomiQ announced encouraging early results from the first patients tested with ProVue Lung. This novel blood-based Laboratory Developed Test (LDT) is designed to support the early detection of lung cancer in high-risk individuals.
PrognomiQ launched ProVue Lung in November 2025 through an Early Experience Program with Penn Highlands Healthcare and Allegheny Health Network. The program is designed to evaluate how the test performs in real-world clinical workflows and how it can be integrated into lung cancer screening pathways.
In the first cohort of 78 high-risk adults, the ProVue Lung blood test accurately detected eight lung cancers. Notably, five of the eight cancers were provisionally categorized as Stage I and all cancers were confirmed by tissue biopsy. All tested individuals in this program were high-risk adults aged 50 and older with a smoking history of at least 20 pack-years, consistent with current U.S. Preventive Services Task Force (USPSTF) screening guidelines.
These early findings translate to a performance of 89% sensitivity to detect all stages of lung cancer at 54% specificity, including 83% sensitivity for Stage I lung cancer. These results represent breakthrough performance for the early detection of lung cancer and could meaningfully enhance the current standard of care, which is low-dose CT (LDCT) scanning. Importantly, these findings align with data from PrognomiQ’s earlier clinical studies, which are currently pending publication.
PrognomiQ’s Early Experience Program is ongoing at Penn Highlands and Allegheny Health with plans to expand to additional health systems in the coming months.
